FDA Panel’s Vote Over Weight-Loss Drug Xenical Results in Tie

BASEL, SWITZERLAND March 16, 1998

The United States Food and Drug Administration’s endocrinologic and metabolic
drugs advisory committee is deadlocked at five to five on recommending
approval of F. Hoffmann-La Roche Ltd.’s weight management drug Xenical®
(orlistat).

Roche said it would meet shortly with the FDA staff to discuss the
recommendation. Roche reaffirms its belief that orlistat has an important role to
play in the management of obesity and looks forward to discussing next steps
with the FDA.

In May 1997 the panel unanimously recommended the approval of Xenical, a
lipase inhibitor which acts in the gastrointestinal tract to decrease fat absorption
by about 30 percent. Drugs in this class do not achieve their effect through brain
chemistry.

Previous studies showed that Xenical-treated patients had statistically significant
reductions in total and LDL cholesterol and systolic and diastolic blood pressure,
as well as improvements in blood concentrations of glucose and insulin after one
year over placebo with diet.

Order Xenical

xenical :: xenical :: xenical :: xenical :: xenical :: xenical :: xenical :: xenical lose weight - lose weight - lose weight - lose weight - lose weight - lose weight lose weight - lose weight - lose weight - lose weight - lose weight - lose weightxenical :: xenical :: xenical :: xenical :: xenical :: xenical :: xenical :: xenical lose weight - lose weight - lose weight - lose weight